| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
7-Hydroxymethyl-10,11-MDCPT-d5 serves as an analytical internal standard and an ADC payload, and thus does not have a defined pharmacological target in the traditional sense. Its primary function in research is to enable FDA/EMA-compliant bioanalytical method validation for ADC pharmacokinetic studies. It corrects for matrix effects, ion suppression, and sample preparation variability in plasma and tissue homogenates. As a camptothecin derivative, the parent molecule targets topoisomerase I, an enzyme involved in DNA replication and transcription.
|
|---|---|
| ln Vitro |
The in vitro activity of 7-Hydroxymethyl-10,11-MDCPT-d5 is defined by its role as a stable isotope-labeled internal standard for LC-MS/MS quantitation. Its +5 Da mass shift supports co-elution and matrix-effect correction. The compound supports metabolic stability assays (microsomal/hepatocyte) for intrinsic clearance determination. As a deuterated analog of a camptothecin derivative, it can be used in ADC payload research for cytotoxicity endpoint review and quantitative payload-release studies.
|
| ln Vivo |
The in vivo activity of 7-Hydroxymethyl-10,11-MDCPT-d5 is not directly applicable as a therapeutic agent, as it is primarily an analytical internal standard and research tool. However, its utility in ADC pharmacokinetic studies supports the in vivo quantification of ADC-released payloads. The deuterated internal standard enables accurate quantitation of payload release in plasma and tissue homogenates, which is critical for understanding ADC biodistribution and efficacy in animal models.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for 7-Hydroxymethyl-10,11-MDCPT-d5 is not applicable in the traditional sense, as the compound is an analytical internal standard rather than an enzyme inhibitor or receptor ligand. However, it is used in LC-MS/MS bioanalytical method validation where it co-elutes identically with the unlabeled analyte while remaining independently detectable via MS. The assay involves spiking the deuterated internal standard into plasma or tissue homogenate samples, followed by extraction and LC-MS/MS analysis to quantify the unlabeled payload.
|
| Cell Assay |
In vitro cell-based assays for 7-Hydroxymethyl-10,11-MDCPT-d5 are not directly applicable, as the compound is primarily an analytical internal standard. However, as a deuterated camptothecin derivative, it may be used in cytotoxicity assays to evaluate ADC payload activity. Cells are treated with the compound or ADC constructs containing this payload, and cell viability is measured using standard assays such as MTT or CellTiter-Glo. The deuterated form can also be used to track payload release and metabolism in cellular uptake studies.
|
| Animal Protocol |
In vivo animal studies for 7-Hydroxymethyl-10,11-MDCPT-d5 are conducted in the context of ADC pharmacokinetic studies. Animals are administered ADC constructs containing the unlabeled payload, and the deuterated compound is used as an internal standard for LC-MS/MS quantitation of the released payload in plasma and tissue homogenates. This enables accurate determination of pharmacokinetic parameters such as Cmax, AUC, and half-life. The internal standard corrects for matrix effects and sample preparation variability.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-Hydroxymethyl-10,11-MDCPT-d5 are characterized by its use as an internal standard for ADC pharmacokinetic studies. It has a molecular weight of 427.42 g/mol and a molecular formula of C22H13D5N2O7. The compound appears as a light yellow to yellow solid with ≥97% purity. Storage recommendations include -20°C, protected from light. The unlabeled CAS number is 428816-69-7. It is supplied for research use only and not for human therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicity information for 7-Hydroxymethyl-10,11-MDCPT-d5 is limited in the available literature. As a research-use deuterated compound, standard safety precautions for handling should be followed. The compound is designated for research use only and is not for human therapeutic applications. It is a controlled substance and not for sale in certain territories. No detailed acute or chronic toxicity data are available from the search results.
|
| References |
|
| Additional Infomation |
7-Hydroxymethyl-10,11-MDCPT-d5 is a deuterated camptothecin derivative that serves as a stable isotope-labeled internal standard for LC-MS/MS bioanalysis. It retains the cytotoxic activity of the parent molecule as an ADC payload while its stable isotope labeling enables precise quantitative analysis. The compound supports FDA/EMA-compliant bioanalytical method validation for ADC pharmacokinetic studies. It has a molecular weight of 427.42 g/mol and formula C22H13D5N2O7. It is intended for research use only.
|
| Molecular Formula |
C22H13D5N2O7
|
|---|---|
| Molecular Weight |
427.42
|
| Appearance |
Light yellow to yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3396 mL | 11.6981 mL | 23.3962 mL | |
| 5 mM | 0.4679 mL | 2.3396 mL | 4.6792 mL | |
| 10 mM | 0.2340 mL | 1.1698 mL | 2.3396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
